Search results
3 dni temu · Table 1 Patient characteristics for all advanced non-small cell lung cancer patients treated with 1 L pembrolizumab mono- or combination therapy in Norway (real-world) or clinical trials (Keynote ...
4 wrz 2024 · A new benchmark for targeted therapies in lung cancer treatment. AEs, adverse events; HR, hazard ratio; NR, not reached; PFS, progression-free survival. Open in viewer.
1 lip 2022 · We curated and analyzed a comprehensive list of therapeutic entities (TEs) in preclinical development and clinical trials for lung cancer. Results On the basis of our analysis of 707 TEs, we found a consistent forward trajectory in the development pipeline for both NSCLC and SCLC.
6 kwi 2024 · 1 Altmetric. Explore all metrics. Abstract. Lung cancer, a multifaceted disease, demands tailored therapeutic approaches due to its diverse subtypes and stages. This comprehensive review explores the intricate landscape of lung cancer research, delving into recent breakthroughs and their implications for diagnosis, therapy, and prevention.
19 sie 2024 · This review examines the latest discoveries in the genetics of lung cancer, discusses key biomarkers, and analyzes current clinical therapies based on this genetic information. It will conclude with a discussion of future prospects and potential research directions.
5 dni temu · Abstract. Since 2011, the US FDA has approved 30 new drugs for use in advanced non–small cell lung cancer (NSCLC), mainly comprising tyrosine kinase inhibitors and immune checkpoint inhibitors. NSCLC with oncogene driver alterations is amenable to treatment with targeted drugs, usually small-molecule inhibitors. In these cases, the demonstration of high overall response rates, coupled with a ...
14 wrz 2024 · This SEER analysis found that immunotherapy improved the survival of Stage 4 NSCLC patients at the population level in the United States. This real-world evidence confirms that immunotherapy has truly revolutionized the management of lung cancer.
